Agenus Inc. , a clinical-stage immuno-oncology company, focuses on the discovery and development of therapies that engage the body’s immune system to fight cancer. The company offers Retrocyte Display, an antibody discovery platform for the identification of fully-human and humanized monoclonal antibodies; SECANT yeast display, an antibody discovery platform used for the generation of novel monoclonal antibodies; and phage display technologies. It is also developing checkpoint modulating antibody candidates targeting GITR, OX40, TIM-3, LAG-3, and others. In addition, the company develops vaccine programs, including Prophage cancer vaccine candidate; AutoSynVax, a synthetic neo-antigen; and PhosPhoSynVax, a vaccine candidate designed to induce immunity against a class of tumor specific neo-epitopes. Further, it develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. Additionally, the company engages in the development of CTLA-4 and PD-1 antagonists; and anti-CTLA-4, CD137, and anti-TIGIT antibodies, as well as various multi-specific antibodies that are under various stages of development. Agenus Inc. has collaboration agreements with Incyte Corporation, Merck Sharpe & Dohme, and Recepta Biopharma SA.; collaboration with Gilead Sciences, Inc. to develop immuno-oncology therapies; and partnership with Phyton Biotech. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.

LATEST NEWSLETTER: Learn what makes our proprietary QS-21 Stimulon a potent #adjuvant and about our efforts to #innovate QS-21 production, supported by a grant of ~1M, recently awarded to $AGEN by the Bill & Melinda Gates Foundation @gatesfoundation. Read https://t.co/coxJZSc2ju

Key highlights from Q1 2019:
-Strong balance sheet following $GILD transaction
-New #clinicaltrial w/ AGEN1181 started and accruing
-Enrollment in lead trials progressing; on track for BLA in 2020
-New INDs (CD137 & PhosphoSynVax #vaccine) on track
https://t.co/snDwADQyLB

2019 started with some exciting #News for us. See our press release to learn about our Q1 2019 Financial Results and other recent updates. https://t.co/QbZFM4nx0M
#oncology #Immunotherapy #innovation

Our Head of Global #Biologics Manufacturing, Al Dadson, joins other industry leaders to discuss bioprocess productivity. Learn how our integrated capabilities from cell-line development to GMP manufacturing are enabling us to deliver #innovation with speed https://t.co/Hmx7su7u0z

Our proprietary QS-21 Stimulon® is a key component in @GSK’s Shingrix vaccine, which GSK projected to surpass £1 B in sales for 2019, its 2nd full year on the market. GSK has pledged an additional $100M towards future production. #vaccines #innovation
https://t.co/jm7o12ZVLM

Load More...

FULL NAME*

What's Your Role?*

WORK EMAIL*

COMPANY NAME*

Company Description*

HOW'D YOU HEAR ABOUT US?

DETAILS ABOUT YOUR GOALS

Agenus Inc.

3 Forbes Road
Lexington, MA 02421

+1 (781) 674-4400

www.agenusbio.com

May 2019
S M T W T F S
« Apr    
 1234
567891011
12131415161718
19202122232425
262728293031  

©2019 ALIGNMT LLC | Alignment Consulting | Mergers & Acquisitions | Investor Relations

CONTACT US

We're not around right now. But you can send us an email and we'll get back to you, asap.

Sending

Log in with your credentials

or    

Forgot your details?

Create Account